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Background: Psoriasis is a chronic inflammatory disease that has a negative impact on patients’ qual-
ity of life. Patients with mild–moderate psoriasis can be treated with topical medications, such as the 
combination drug calcipotriol/betamethasone dipropionate (Cal/BD).  
Objectives: This study investigated the adherence of psoriasis patients to therapy with Cal/BD aerosol 
foam, as well as their satisfaction with the treatment’s efficacy, safety, and effect on their quality of life.
Methods: Patients with mild–moderate plaque psoriasis were eligible to participate in this open-label, 
non-placebo controlled, prospective single-center study. Adherence to treatment was assessed using the 
Morisky-Green scale 4 and 12 weeks after the start of treatment. Satisfaction with the treatment was 
assessed using the abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). The 
severity of psoriasis was assessed on the mIGA and PGA scales, and the impact on quality of life was 
assessed using the PDI and DLQI scales.
Results: A total of 65 patients entered the study. Adherence to treatment was good, with 73.8% of 
patients showing high adherence at 12 weeks. Satisfaction was also good, with 46 patients (70.8%) 
being completely satisfied.
ABSTRACT
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Introduction
Psoriasis is a chronic inflammatory disease that affects 2%–4% 
of the western population [1]. It is characterized by the for-
mation of well-defined erythematous-squamous plaques and a 
complex immune mechanism [2]. Psoriasis is recognized by the 
World Health Organization as a debilitating, painful disease 
[3]. The association of comorbidities such as psoriatic arthrop-
athy and the risk of cardiovascular disease make psoriasis a 
systemic disease. The disease has a psychological impact on 
patients, who have a greater risk of depression, anxiety, and 
even social stigmatization [4]. All of these have a significant 
negative impact on the patients’ quality of life.
The development in recent years of biological drugs has 
revolutionized the treatment of psoriasis. However, topical 
medications are considered the cornerstone of therapy for 
many patients [5]. Patients with a score less than 10 on a 
psoriasis severity index (eg, PASI, BSA, or DLQI) can be 
treated with topical monotherapy. Patients with moderate 
plaque psoriasis who were treated with calcipotriol/beta-
methasone dipropionate (Cal/BD) aerosol foam for 4 weeks 
achieved a Psoriasis Area and Severity Index (PASI) score 
of 75, which was higher than that achieved with 12-week 
methotrexate and acitretin therapy but similar to that with 
fumaric acid esters [6]. This finding reaffirms the indication 
for topical treatment in patients with mild–moderate plaque 
psoriasis.
Current guidelines recommend the topical use of a vita-
min D analog (eg, calcipotriol) and a corticosteroid (eg, 
betamethasone dipropionate) as the first-line treatment for 
plaque psoriasis. The latest Cochrane review on treatments 
for psoriasis [7] reported that the combined use of these drugs 
from different pharmacological groups is superior in efficacy 
and safety to their use separately. The combination of 0.005% 
calcipotriol and 0.064% betamethasone dipropionate has a 
lower rate of side effects than observed with topical cortico-
steroids (mainly skin atrophy) and vitamin D analogs (skin 
irritation and hypercalcemia) used separately.
A new aerosol foam formulation of Cal/BD (Enstilar) for 
the treatment of plaque psoriasis was introduced in 2017. 
In an in vitro model of skin penetration of Cal/BD aerosol 
foam, greater diffusion of both drugs and more stable skin 
concentrations were demonstrated [8]. The anti-psoriatic 
effect of Cal/BD aerosol foam was superior to that observed 
with galenic ointment [9]. Regarding safety, the MUSE study 
[10] demonstrated a good safety profile, and the PSO-FAST 
study [11] demonstrated efficacy and tolerability in patients 
with psoriasis of any severity level.
Adherence to topical treatment depends on multiple factors 
regarding the product itself and the patient. Cosmetics and 
speed of action are essential for the patient to correctly comply 
with the drug dosage. However, other social and even occupa-
tional factors can significantly influence adherence. The main 
objective of this study was to determine the adherence to treat-
ment with Cal/BD aerosol foam in patients with mild–moderate 
plaque psoriasis 4 weeks after starting treatment. The secondary 
objectives were to evaluate the: (a) degree of patient satisfaction 
during and after treatment termination, and (b) treatment’ effi-
cacy, safety, and impact on the patients’ quality of life.
Methods
Patients
From November 2017 to November 2019, we recruited 
patients from the Dermatology Department at San Cecilio 
University Hospital. Patients were eligible for the study if they 
were older than 18 years of age and had a clinical diagnosis 
of plaque psoriasis on the trunk and extremities for at least 
6 months, with an affected body surface area (BSA) <10%, 
a PASI <10, and a Dermatology Life Quality Index (DLQI) 
score <10. Other inclusion criteria were the ability to apply 
the treatment or, failing that, to be assisted by personnel who 
could apply it. Moreover, their scores on the Physician Global 
Assessment (PGA), modified Investigator’s Global Assessment 
(mIGA), and modified PASI (excluding the head) had to show 
at least a slight effect of improvement.
Exclusion criteria were psoriasis in areas other than the 
trunk and extremities (eg, scalp, face, genitals, and skin folds), 
a history of allergy to vitamin D analogs or topical cortico-
steroids, and concurrent or previous treatment with systemic 
corticosteroids, retinoids (eg, acitretin) or immunosuppres-
sants (eg, methotrexate, cyclosporine, fumaric acid esters) 
in the past 4 weeks, etanercept (past 4 weeks), adalimumab 
or infliximab (past 8 weeks), ustekinumab (past 16 weeks), 
other biologics (past 4 weeks or 5 half-lives), psoralen (past 4 
weeks), or UVA or UVB phototherapy (past 2 weeks). Other 
exclusion criteria were: a likelihood of excessive sun exposure 
during the study, disorders of calcium metabolism associated 
with hypercalcemia, skin infections, severe liver or kidney 
disorders, and a recent diagnosis of other psoriasis types (eg, 
guttate, erythrodermic, pustular, or exfoliative psoriasis).
Conclusions: Over a 4-week period, patients treated with Cal/BD aerosol foam had significant im-
provement in disease severity that was directly related to treatment adherence.
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Study Design
This was an open-label, non-placebo controlled, prospective 
single-center study. The study protocol was approved by the 
ethics committee of our hospital on 19 oct 2019, with the code 
Derm_003_2019. The study was carried out in compliance with 
the principles of the Declaration of Helsinki and good clinical 
practice. All patients gave written informed consent.
Patients who had previously used antipsoriatic or other 
relevant treatments underwent a pharmacological “washout 
period” of at least 4 weeks before starting the study. All 
patients were educated on how to apply Cal/BD aerosol foam, 
with the first application directly observed by an investigator. 
The medication was applied only to the psoriasis plaques of 
the trunk and extremities, avoiding its use in areas such as 
the scalp, face, genitals, and skin folds. Cal/BD aerosol foam 
was applied once a day according to the technical datasheet. 
Complete resolution of the lesions was considered a reason 
for discontinuation of the treatment, while the reappearance 
of lesions allowed the resumption of treatment. Continuous, 
uninterrupted use of Cal/BD (once per day) was permitted for 
a maximum period of 4 weeks. 
Evaluations were performed at baseline (visit 0) and at 
each study visit (week 4 and week 12). Adherence to treat-
ment was assessed using the Morisky-Green-Levine scale, 4 
weeks and 12 weeks after the start of treatment. The number 
of cans used by each patient was quantified. The degree of 
patient satisfaction with the treatment was assessed using the 
abbreviated Treatment Satisfaction Questionnaire for Medi-
cation (TSQM-9) scale at 4 weeks, and at 12 weeks in those 
patients who restarted treatment due to regrowth of lesions.
The severity of psoriasis was assessed using the mIGA and 
PGA scales, and the impact on quality of life was assessed using 
the Psoriasis Disability Index (PDI) and the DLQI. The extent 
and severity of clinical signs of psoriasis lesions were evaluated 
using the mPASI. The extent of psoriasis involvement was 
recorded as a function of the affected body surface area (BSA).
Safety and tolerability were evaluated after 4 weeks 
of treatment with Cal/BD aerosol foam, and again at 12 
weeks in patients who restarted topical treatment due to the 
regrowth of psoriasis plaques. Serious adverse events and 
adverse drug reactions  were recorded.
Statistical Analysis
All analyses were performed using the Stata statistical pro-
gram version 16.0 for MacOS (StataCorp) and the level of sig-
nificance was set at P < 0.05. Graphics were made using Graph-
Pad Prism version 8.0.0 for MacOS (GraphPad Software). 
Results
The study enrolled 65 patients with plaque psoriasis, 
including 33 men and 32 women, with a mean age of 39.7 
years (range, 18–70 years). Regarding the duration of psoria-
sis, for 36 patients it was less than 5 years, for 9 patients it was 
between 5 and 10 years, and for 20 patients it was greater than 
10 years. No patient had previously undergone treatment with 
acitretin, 22 patients (33.8%) had used methotrexate, 12 had 
used cyclosporine, and only 1 patient had undergone biologi-
cal treatment with etanercept (suspended in 2016 by personal 
decision). Regarding previous treatments for psoriasis, 40 
patients (61.5%) had previously used topical corticosteroids 
and 39 patients (60%) had previously used Cal/BD gel.
Treatment Adherence and Satisfaction
At 4 weeks (visit 1), adherence to treatment with Cal/BD 
aerosol foam was high on the Morisky-Green-Levine scale in 
100% of the participants. At 12 weeks (visit 2), 48 patients 
(73.8%) showed high adherence, 14 patients (21.5%) had 
moderate adherence, 2 patients had poor adherence, and 1 
patient was not adhering to the treatment (Figure 1).
Patient-reported satisfaction was evaluated using the 
validated TSQM-9 scale at 4 weeks (visit 1): 46 patients 
(70.8%) were completely satisfied with the treatment, 8 
patients (12.3%) were moderately satisfied, and 11 patients 
(16.9%) were mildly satisfied. The 12-week score (visit 2) 
on the TSQM-9 scale showed that 55 patients (84.6%) were 
completely satisfied with the treatment, 1 patient was moder-
ately satisfied, and 9 patients (13,9%) were mildly satisfied. 
Patients were divided into 3 groups on the basis of their 
treatment adherence, and the mean TSQM-9 score was cal-
culated for each group (Figure 2). There was a significant 
difference in TSQM-9 scores between patients who had high 
adherence to treatment and those who had low or no adher-
ence (t = 32,573; P = 0.007).
A Kruskal-Wallis test was performed to check for sig-
nificant intergroup differences. A significant relationship 
between adherence and efficacy was evident, and there were 
also significant intergroup differences in favor of high adher-
ence in all comparisons. The results are reported in Table 2.
Efficacy
The evolution of psoriasis severity (assessed with PASI, 
BSA) is shown in Figure 3. The evolution of psoriasis sever-
ity (assessed with BSA) according to treatment adherence is 
shown in Figure 4.
The mean IGA score was 1.954 (SD = 0.891) at the base-
line visit, 0.94 (SD = 0.982) at visit 1, and 0.62 (SD = 1.128) 
at visit 2. The mean PGA score was 2.8 (SD = 0.905) at the 
baseline visit, 1.19 (SD = 1.211) at visit 1, and 0.77 (SD = 
1.1487) at visit 2. 
Patients with psoriasis of less than 5 years’ duration had a 
good response to topical treatment with Cal/BD aerosol foam, 
with a mean PASI score at week 4 of 0.49 (SD = 0.70) and at 
week 12 of 0.13 (SD 0.30) (P <0.01). Patients with psoriasis 
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Table 1. Characteristics of the 65 Patients with Plaque Psoriasis, at Inclusion 
Characteristic Value









Secondary school 20 (30.8)
High school certificate 28 (43.1)
Tertiary 17(26.2)
Occupational status, n (%)
Working or studying 13 (20.0)
Unemployed or disabled 42 (64.6)
Retired 10 (15.4)
Duration of psoriasis, years mean (SD) 9.5 (9.5)
Previous therapy with topical drugs, n (%)
Topical corticosteroids 40 (61.5)
Vitamin D3 analogs 8 (12.0)
Cal/BD gel (Daivobet) 39 (60.0)




Fumaric acid ester 0 (0)
Biological drugs 1 (1.5)
None (46.2)
SD = standard deviation.
Figure 1. Morisky-Green scores for adherence to Cal/BD treatment at 12 weeks (visit 2). High adher-










of more than 10 years’ evolution had a poor response to Cal/
BD aerosol foam, with no significant change in PASI scores 
from week 4 (mean = 2.45; SD = 1.71) to week 12 (mean = 
2.15; SD = 2.41; P = 1). 
Quality of Life, Safety and Satisfaction
The mean DLQI score was 10.67 (SD = 4.96) at the 
baseline visit, 2.41 (SD = 3.87) at visit 1, and 2.24 (SD = 
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5.25) at visit 2. The mean PDI score was 21.37 (SD = 9.63) 
at the baseline visit, 5.94 (SD = 7.64) at visit 1, and 4.41 (SD 
= 9.92) at visit 2.
No patient had side effects related to application of Cal/
BD aerosol foam. Regarding its cosmetic properties, 15.4% 
responded that the product’s most important attribute was 
that it did not leave residues or spots on the skin, 7.7% 
valued the absence of odor, and 76.9% rated it as without 
data. Patients reported as the most important interest the 
easy application of the drug to the skin. The overall cosmetic 
quality of Cal/BD aerosol foam was rated “good” by 90.8% 
of the participants. 
In terms of general satisfaction with Cal/BD aerosol 
foam, 66.2% of the patients were very satisfied, 15.4% was 
satisfied, 10.8% was not very satisfied, and 7.7% was not at 
all satisfied. The patients reporting little or no satisfaction 
corresponded to those in whom psoriasis did not improve 
with the treatment.
Discussion
Stein et al [12], among others, reported that the high effi-
cacy of Cal/BD aerosol foam is an important characteristic in 
the treatment of mild-moderate plaque psoriasis. Its speed of 
action, in patients with mild or moderate psoriasis, deserves 
to be reviewed [13]. This study evaluated the adherence and 
satisfaction of patients with plaque psoriasis on the trunk 
and extremities treated with Cal/BD aerosol foam. Over a 
4-week period, patients treated with Cal/BD aerosol foam 
had a significant improvement in disease severity that was 
directly related to treatment adherence.
Non-compliance with topical therapy continues to be 
a challenge in clinical practice for patients with psoriasis, 
and constitutes a key limiting factor in its effectiveness [14]. 
According to the results obtained using the Morisky-Green-
Levine scale, at 12 weeks only 73.8% of the participants were 
fully compliant with the treatment. This lack of adherence 
was due to the lack of response to treatment, coinciding in 
those patients with psoriasis duration of more than 10 years. 
These patients, who previously had systemic treatment, 
received treatment with systemic or biological therapy after 
the study ended. 
The reason why therapeutic compliance extends up to 
12 weeks is directly related to the effectiveness of Cal/BD 
aerosol foam beyond the 4 weeks indicated in the datasheet, 
as demonstrated by Paul et al. [15]. The most frequent diffi-
culties associated with non-compliance are the patients’ per-
ception of the effectiveness of the product and the discomfort 
of the administration regimen. As observed in our study, both 
difficulties have been overcome with this new formulation. 
The quick and effective response to treatment has a direct 
impact on treatment compliance. Patient expectations are 
directly linked to therapeutic adherence [16], and treatment 
failure plays the main role in abandoning therapy, especially 
in topical treatments.
The secondary objective of the study was to assess patient 
satisfaction after Cal/BD aerosol foam treatment. The results 
show how patient satisfaction after treatment was maintained 
over time. Low satisfaction or dissatisfaction with the treat-
ment, recorded in 9 patients, was justified by their having a 
partial or no response to the treatment. However, the cosmetic 
evaluation of the product by these patients was positive.
As previously reported, low adherence to treatment 
may be justified by the acceptability of the vehicle and 
its cosmetics [17]. The Cal/BD aerosol foam formula was 
developed to provide patients with comfortable and easy 
topical application. This allows for greater adherence to 
treatment compared with other topical formulations for the 
treatment of psoriasis. Treatment adherence—an essential 
objective in chronic skin diseases such as psoriasis—and 



















LOW OR NO ADHERENCE
Figure 2. Patient satisfaction with Cal/BD treatment, scored on the TSQM-9 scale, according 
to treatment adherence. Values are mean and SD
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Another variable recorded during the study was the num-
ber of packages used during treatment and follow-up at 12 
weeks. Of the participants, 87.6% consumed only 2 cans of 
Cal/BD aerosol foam. With these data we corroborate what 
was published by Balak et al. [18] and Duvetorp et al. [19], 
who considered this medication a cost-effective treatment for 
plaque psoriasis. Our results regarding treatment adherence, 
effectiveness, and tolerability of Cal/BD aerosol foam support 
the conclusions of a recent review of studies on the use of Cal/
BD aerosol foam in clinical practice [20]. 
The safety of Cal/BD aerosol foam further strengthens 
its indication as the first line of therapy in patients with 
mild–moderate plaque psoriasis [21]. In a study, 60% of 
participants who had previously used Cal/BD gel were asked 
to compare the two formulations, and 95% said that the new 
formulation was better, mainly due to its efficacy and cosmet-
ics (non-greasy feel and absence of residue); the remaining 
5% considered the gel and foam formulations to be similar 
in efficacy and cosmetics. 
The effectiveness of Cal/BD aerosol foam is essential 
for adherence to treatment. This drug combination inhibits 
the production of one of the most important interleukins in 
psoriasis, IL-17, and decreases its blood level [22]. However, 
the vasoconstrictive power of the corticosteroid in the new 
aerosol foam formulation is not superior to that in the gel 
formulation [23].
This study has limitations due to the small number of 
enrolled patients. A multicenter study with the participation 


























Figure 3. Evolution of psoriasis severity during Cal/BD treatment. Values are 
mean and SD . PASI = Psoriasis Area and Severity Index; BSA = Body surface 
area
Figure 4. Evolution of psoriasis severity (BSA) according to treatment adherence. Values are mean and SD. BSA 
= Body surface area
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Conclusions
This 12-week study in patients with plaque psoriasis on 
the trunk and extremities showed that Cal/BD aerosol foam 
provides a significant improvement in its treatment, with very 
good adherence and a favorable safety profile. The high level 
of adherence, the rapid action of the drug, and the adequate 
cosmetics of the vehicle make Cal/BD in aerosol foam a first-
line topical treatment in patients with plaque psoriasis. Cal/
BD aerosol foam can be considered a cost-effective drug for 
the treatment of plaque psoriasis.
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